BioNTech, the Germany-based biotech company, saw a 10% increase in its ADRs after announcing positive results from a phase 3 clinical trial of its cancer drug trastuzumab pamirtecan in collaboration with Chinese peer Duality Biologics. The treatment met its primary endpoint of progression-free survival in patients with unresectable or metastatic breast cancer. This marks BioNTech’s first late-stage oncology drug to meet its primary endpoint. The companies plan to file for regulatory approval in China, the EU, and the US, with potential for significant market impact due to high numbers of breast cancer cases globally.

Read more at Yahoo Finance: Why BioNTech Stock Crushed the Market Today